Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesThe Cost of Dementia in Europe: A Review of the Evidence, and Methodological Considerations
PharmacoEconomics, 07/13/09
Jonsson L et al. - The costs of AD in Europe are substantial and increase with disease severity. Methodological differences between studies make comparison across countries and healthcare systems difficult, and there is a need to standardize methods for assessing and valuing informal care. Patient-level information on resource use is required to analyse determinants of care costs and predict the impact of therapeutic interventions. More data are needed to support future economic evaluations of therapies for AD.
Related Articles
Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008
BMC Neurology, 10/23/09
Relevance Score: 94%
High Prevalence of Orthostatic Hypotension in Mild Dementia
Dementia and Geriatric Cognitive Disorders, 10/15/09
Relevance Score: 93%
Predicting dementia: role of dementia risk indices
Future Neurology, 10/02/09
Relevance Score: 93%
Lipids peroxidation markers in Alzheimer's disease and vascular dementia
Geriatrics and Gerontology International, 11/17/09
Relevance Score: 91%
Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications
Medical Hypotheses, 10/05/09
Relevance Score: 91%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/07/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Costs and benefits of dropout schedules of test-restudy practice: Implications for student learning
Applied Cognitive Psychology, 12/07/09
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
PLoS Medicine, 12/04/09
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Sponsor
Article Search
Sponsor